Argatroban

CHEMBL1166 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

508.6 g/mol

LogP

1.3

Phase

4

A direct thrombin inhibitor that binds to and blocks the active site of thrombin, preventing it from converting fibrinogen to fibrin and forming blood clots. It is used to prevent and treat clotting in patients with heparin-induced thrombocytopenia.

Moleküler Ağırlık

508,6000 g/mol

LogP

1,30

TPSA

189,00 Å²

Lipinski RO5

Geçer

Terapötik Alanlar

Stroke Deep Vein Thrombosis / Pulmonary Embolism

Etki Mekanizması

Binds to antithrombin III, dramatically accelerating its inhibition of thrombin (Factor IIa), Factor Xa, and other serine proteases of the coagulation cascade. This produces rapid anticoagulation proportional to the dose administered.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Binds to antithrombin III, dramatically accelerating its inhibition of thrombin (Factor IIa), Factor Xa, and other serine proteases of the coagulation cascade. This produces rapid anticoagulation proportional to the dose …

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

CC1CNc2c(cccc2S(=O)(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CC[C@@H](C)C[C@@H]2C(=O)O)C1

InChI

InChI=1S/C23H36N6O5S/c1-14-8-10-29(18(12-14)22(31)32)21(30)17(6-4-9-26-23(24)25)28-35(33,34)19-7-3-5-16-11-15(2)13-27-20(16)19/h3,5,7,14-15,17-18,27-28H,4,6,8-13H2,1-2H3,(H,31,32)(H4,24,25,26)/t14-,15?,17+,18-/m1/s1

Molecular Formula

C23H36N6O5S

HBD / HBA

5 / 8

Döndürülebilir Bağlar

9

Ağır Atomlar

35

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

A direct thrombin inhibitor that binds to and blocks the active site of thrombin, preventing it from converting fibrinogen to fibrin and forming blood clots. It is used to prevent and treat clotting in patients with heparin-induced thrombocytopenia.

Binds to antithrombin III, dramatically accelerating its inhibition of thrombin (Factor IIa), Factor Xa, and other serine proteases of the coagulation cascade. This produces rapid anticoagulation proportional to the dose administered.

Yes, Argatroban is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1166. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 92722. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Argatroban PillFYI'da

Yapı

Hızlı Veriler

Formül: C23H36N6O5S

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.